Company profile
Oculis Holding AG
NASDAQ:OCSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Licaminlimab | phase2_3 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07548632 | phase2_3 | recruiting | 2026-04-16 | 2026-12-01 | Oculis | A Clinical Study Evaluating Licaminlimab for Dry Eye Disease |
| NCT05147233 | phase3 | completed | 2022-06-24 | 2023-06-22 | Oculis | A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery |
| NCT06128369 | phase3 | terminated | 2023-12-18 | 2024-05-02 | Oculis | A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery |
| NCT05066997 | phase2_3 | completed | 2021-10-19 | 2026-04-10 | Oculis | A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) |
| NCT06172257 | phase3 | completed | 2024-03-15 | 2026-04-02 | Oculis | A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) |
FDA applications (0)
No records yet.